GenVec

From Wikipedia, the free encyclopedia
Jump to: navigation, search
GenVec, Inc.
Type Public company
Traded as NASDAQGNVC
Industry Pharmaceuticals
Headquarters Gaithersburg, Maryland, United States
Key people Cynthia Collins, President and CEO
Douglas J. Swirsky, Senior Vice President and Chief Financial Officer
Products TNFeradeTM Phase III
Revenue $13.9 million (2009)
Net income Decrease$18.4 million (2009)
Employees 85
Website www.genvec.com

GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. GenVec currently has a collaboration with Novartis AG to develop treatments for hearing loss and balance disorders worldwide. GenVec is also working with companies and organizations such as Merial, and the U.S. Government on vaccine development. The U.S. Department of Agriculture's Animal and Plant Health Inspection Service (APHIS) gave conditional approval to GenVec's foot-and-mouth disease (FMD) vaccine in the middle of 2012. This was a significant achievement as it marked GenVec's first approved product. In June 2001, GenVec announced the issuance of a U.S. patent covering formulation methods for preserving adenovectors.[1] In Aug 2006, GenVec entered the first human therapeutic clinical trial involving the company's adenoviral-vector technology used in an HIV vaccine candidate at Vaccine Research Center at NIH.[2]


TNFerade[edit]

TNFerade (the Company's previous lead product candidate) failed a phase III trial for pancreatic cancer. There was an 8% reduction in risk of death but it was not statistically significant.[3] TNFerade is “an adenovector, or DNA carrier, which contains the gene for tumor necrosis factor-alpha (TNFα), an immune system protein, for direct injection into tumors”.[3]

References[edit]